On October 15, 2009, Immunomedics, Inc., a Delaware corporation (the "Company"), issued a press release announcing further topline results for epratuzumab Phase IIb study in systemic lupus erythematosus (SLE). The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.1 hereto and is incorporated by reference herein.

(d) Exhibits.

Exhibit No.     Description

                Press Release of Immunomedics, Inc. dated October 15, 2009
99.1            announcing further topline results for epratuzumab Phase IIb study
                in systemic lupus erythematosus (SLE).